Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. [electronic resource]
Producer: 20080228Description: 897-906 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Animals
- Antineoplastic Agents -- blood
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Cell Proliferation -- drug effects
- Chemotherapy, Adjuvant
- ErbB Receptors -- metabolism
- Erlotinib Hydrochloride
- Female
- Humans
- Immunohistochemistry
- In Situ Nick-End Labeling
- Ki-67 Antigen -- metabolism
- Mice
- Mice, Nude
- Middle Aged
- Neoadjuvant Therapy -- methods
- Neoplasm Staging
- Neoplasms, Hormone-Dependent -- drug therapy
- Protein Kinase Inhibitors -- blood
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Quinazolines -- blood
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Signal Transduction -- drug effects
- Tandem Mass Spectrometry
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.